Emergent BioSolutions Hosts Biopreparedness Forum for Members of the NATO Parliamentary Assembly

May 6, 2010

ROCKVILLE, Md., May 06, 2010 (BUSINESS WIRE) --Emergent BioSolutions Inc. (NYSE:EBS) is hosting "Bioterrorism Prevention, Preparedness and Response," a forum uniquely organized for members of the North Atlantic Treaty Organization (NATO) Parliamentary Assembly (PA). The one-day event is an interactive discussion related to biopreparedness strategies and best practices such as funding, development, and manufacture of biodefense medical countermeasures, creation of strategic stockpiles, and cooperation within the international community.

"Emergent is pleased to organize this forum for NATO parliamentarians as part of our efforts to raise global awareness of biopreparedness," said Allen Shofe, senior vice president public affairs, Emergent BioSolutions. "Central to our goal of fostering cooperation within the international community is our Company's extensive, decade-long experience in the development, manufacture, and delivery of medical countermeasures that are critical to the U.S. government's biodefense infrastructure."

"Strengthening the Biological Weapons Convention and international cooperation in biodefense are of paramount importance. This forum organized by Emergent is extremely valuable in helping us, as national legislators, to obtain more information on biopreparedness and to promote the idea of strengthening national biodefense capabilities using the best practices and expertise developed by our Allies," said Canadian Senator Pierre Claude Nolin, NATO PA Treasurer and Vice Chairman of the NATO PA Science and Technology Committee. "We are firm believers in international mechanisms to address bioterrorism challenges."

Emergent BioSolutions' senior management team, headed by Fuad El-Hibri, chairman and chief executive officer and Daniel J. Abdun-Nabi, president and chief operating officer, are joined by other biopreparedness experts, to provide an overview of the United States' approach to bioterrorism prevention, the role of the Department of Defense and the importance of coordination of international efforts. Featured speakers include: Congressman Mike Rogers (R-MI), Dr. Robert P. Kadlec, Director of PRTM Biodefense and Public Health Practice, Jim Saxton, former Member of the U.S. House of Representatives, and Dr. Tevi Troy, Senior Visiting Fellow at the Hudson Institute and former Deputy Director of the U.S. Department of Health and Human Services.

The visiting delegation, led by NATO Officers of the Science and Technology Committee, is composed of parliamentarians from representative NATO nations including Canada, the Czech Republic, France, and Portugal. The forum is taking place in Washington, D.C.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax disease. Emergent's product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

About the NATO Parliamentary Assembly

The NATO Parliamentary Assembly is the inter-parliamentary organization of legislators from the member countries of the North Atlantic Alliance as well as 14 associate members. The Assembly provides a critical forum for international parliamentary dialogue on an array of security, political and economic matters. For more information, visit www.nato-pa.int.

SOURCE: Emergent BioSolutions Inc.

Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
+1-301-795-1877
BurrowsR@ebsi.com
or
Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
+1-301-795-1800
SchmittT@ebsi.com